Form 4: Entrada Therapeutics' President & COO, Nathan Dowden, Reports Stock Transactions

Nathan Dowden, President & COO of Entrada Therapeutics, reports the acquisition and disposal of common stock and stock options, including grants of restricted stock units and sales to cover tax obligations.

Summary

• On March 1, 2024, Nathan Dowden, President & COO of Entrada Therapeutics, received a grant of 33,100 restricted stock units (RSUs) that vest in four installments from March 1, 2025, to March 1, 2028.
• Dowden also received a grant of 60,000 RSUs on March 1, 2024, vesting in two installments on March 1, 2026, and March 1, 2027.
• Additionally, Dowden acquired 50,100 stock options on March 1, 2024, with 25% vesting on March 1, 2025, and the remainder vesting monthly until March 1, 2028.
• Between March 4 and March 5, 2024, Dowden sold a total of 2,238 shares of common stock to cover tax withholding obligations related to the vesting of previously granted RSUs, at prices ranging from $12.03 to $13.82.
• Following these transactions, Dowden directly owns 139,030 shares of common stock and 50,100 stock options.

Sentiment

Score: 6

Explanation: The document reflects standard executive compensation practices and stock transactions, indicating a neutral sentiment. The grants suggest confidence in the company's future, while the sales are routine for tax purposes.

Positives

• The grant of RSUs and stock options to the President & COO aligns his interests with the long-term success of the company.
• The vesting schedules of the RSUs and stock options incentivize continued service and commitment to Entrada Therapeutics.

Negatives

• The sale of shares to cover tax obligations, while common, slightly reduces Dowden's direct ownership in the company.

Risks

• Future fluctuations in the stock price could impact the value of the RSUs and stock options.
• Changes in Dowden's employment status could affect the vesting of the RSUs and stock options.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules of the RSUs and stock options suggest a continued commitment from the executive to the company's future.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The grants of RSUs and stock options are common compensation practices used to align executive incentives with shareholder value.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices in the biotechnology industry, often used to attract and retain talent.
• Vesting schedules similar to those described in the document are common, typically spanning several years to incentivize long-term commitment.
• Sales of shares to cover tax obligations are also a routine occurrence among executives receiving equity compensation.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding executive compensation and ownership.
• The vesting schedules incentivize the executive to contribute to the company's long-term success, benefiting shareholders.

Key Dates